Alzheimer’s vaccine research has progressed significantly since the disease was first identified over a hundred years ago, with treatments now available that can reduce harmful proteins in the brain associated with the condition. Vaccine trials are currently underway to eliminate these proteins, with one of the most promising candidates being UB-311 developed by American company Vaxxinity. The synthetic, peptide-based immunotherapy has proved safe and tolerable in phase 2 trials and Japanese healthcare company Eisai recently developed LEQEMBI, a cost-effective vaccine for the disease.
DeepSeek iOS app sends data unencrypted to ByteDance-controlled servers
DeepSeek, an app by ByteDance, sends data, including encrypted information, to servers located in China, leading to concerns over privacy breaches. After security firm Wiz
